Understanding and preventing heart problems from chemotherapy in African American children
Predicting and Preventing Chemotherapy-Induced Cardiotoxicity in African American Children
This study is looking at how the chemotherapy drug doxorubicin might affect the hearts of African American children with cancer, and it wants to find out if certain genes can help predict who might have heart problems after treatment, so we can find better ways to keep these kids safe while they fight cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University at Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-11059720 on NIH RePORTER |
What this research studies
This research investigates the risk of heart damage caused by the chemotherapy drug doxorubicin in African American children with cancer. It aims to identify genetic factors that may predict which patients are more likely to experience heart issues after treatment. By using patient-specific stem cells, the study will explore innovative methods to prevent these complications. The goal is to improve the safety and effectiveness of cancer treatments for this vulnerable population.
Who could benefit from this research
Good fit: Ideal candidates for this research are African American children aged 0-11 years who are receiving doxorubicin as part of their cancer treatment.
Not a fit: Patients who are not African American or those who are not receiving doxorubicin for their cancer treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better prediction and prevention of heart problems in children undergoing chemotherapy, ultimately improving their long-term health outcomes.
How similar studies have performed: While there has been significant research on chemotherapy-induced cardiotoxicity, this approach using patient-specific stem cells is relatively novel and has not been extensively tested in this specific population.
Where this research is happening
Chicago, United States
- Northwestern University at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Burridge, Paul W. — Northwestern University at Chicago
- Study coordinator: Burridge, Paul W.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.